Show simple item record

dc.contributor.authorAlhassan, E.
dc.contributor.authorJohnson, J.
dc.contributor.authorNakity, R.
dc.date.accessioned2020-04-27T19:48:55Z
dc.date.available2020-04-27T19:48:55Z
dc.date.issued2020
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85083163200&doi=10.12659%2fAJCR.920681&partnerID=40&md5=9d61ebdf97a3d97f3a8c91eea2664a6f
dc.identifier.urihttp://hdl.handle.net/10713/12653
dc.description.abstractPatient: Female, 59-year-old Final Diagnosis: Granulomatosis with polyangiitis Symptoms: Dyspnea Medication: Rituximab Clinical Procedure: - Specialty: Rheumatology Objective: Diagnostic/therapeutic accidents Background: Rituximab is a genetically engineered chimeric (murine-human) monoclonal antibody (mAb) directed against CD20 antigen on the surface of B cells. Commonly reported adverse effects are chills and fevers, which are usually associated with the first infusion. Recent studies have shown an association between rituximab use and low immunoglobulin (Ig) level due to a reduction in plasma cell precursors, which leads to an increased risk of infections with the use of rituximab. Case Report: We present a case of hypogammaglobulinemia associated with rituximab use in a patient with Granulomatosis with Polyangiitis (GPA). A 59-year-old woman presented with shortness of breath. After an extensive workup, she was diagnosed with GPA. She received rituximab for the induction of remission. Laboratory workup, which was done five days after she received the second rituximab dose, showed IgG and IgM levels below the level of normal. One month after her second dose of rituximab, she presented to the Medical Intensive Care Unit as a transfer from an outside facility intubated and sedated due to acute respiratory failure secondary to sep-tic shock with E. coli bacteremia. The patient died on admission despite aggressive management, including the ACLS protocol. Conclusions: Rituximab is an effective medication in the management of ANCA-associated vasculitis. Obtaining an immuno-globulin level at baseline and before each rituximab cycle is of great clinical importance and helps guide physicians in prescribing B cell-targeted therapy.en_US
dc.description.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171369/en_US
dc.language.isoen_USen_US
dc.publisherInternational Scientific Information, Inc.en_US
dc.relation.ispartofAmerican Journal of Case Reports
dc.subjectImmunoglobulin Gen_US
dc.subjectImmunotherapyen_US
dc.subjectMeSH Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitisen_US
dc.titleRituximab use and hypogammaglobulinemiaen_US
dc.typeArticleen_US
dc.identifier.doi10.12659/AJCR.920681
dc.identifier.pmid32269210


This item appears in the following Collection(s)

Show simple item record